Meenakshi Devidas

List of Publications by Citations

385 papers	22,075 citations	79 h-index	144 g-index
402 ext. papers	25,854 ext. citations	5.2 avg, IF	5.99 L-index

#	Paper	IF	Citations
385	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature*, **2012**, 481, 157-63	50.4	1163
384	Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. *New England Journal of Medicine*, **2009**, 360, 470-80	59.2	1030
383	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. *New England Journal of Medicine*, **2014**, 371, 1005-15	59.2	885
382	Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. *Journal of Clinical Oncology*, **2012**, 30, 1663-9	2.2	758
381	Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. *Blood*, **2008**, 111, 5477-85	2.2	621
380	Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. *Journal of Clinical Oncology*, **2009**, 27, 5175-81	2.2	540
379	Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. *Cancer Cell*, **2012**, 22, 153-66	24.3	515
378	The genomic landscape of hypodiploid acute lymphoblastic leukemia. *Nature Genetics*, **2013**, 45, 242-52	36.3	474
377	JAK mutations in high-risk childhood acute lymphoblastic leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 9414-8	11.5	446
376	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. *Nature Genetics*, **2017**, 49, 1211-1218	36.3	430
375	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. *Blood*, **2010**, 115, 5312-21	2.2	425
374	Germline genomic variants associated with childhood acute lymphoblastic leukemia. *Nature Genetics*, **2009**, 41, 1001-5	36.3	383
373	Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. *Leukemia*, **2008**, 22, 2142-50	10.7	379
372	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). *Blood*, **2007**, 109, 926-35	2.2	338
371	Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. *Blood*, **2010**, 116, 4874-84	2.2	315
370	Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. *Journal of Clinical Oncology*, **2003**, 21, 1574-80	2.2	305
369	Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. *Leukemia*, **2014**, 28, 1467-71	10.7	298

368	Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. *Journal of Clinical Oncology*, **2009**, 27, 2536-41	2.2	254
367	Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. *Journal of Clinical Oncology*, **2005**, 23, 3376-82	2.2	245
366	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. *Journal of Clinical Oncology*, **2016**, 34, 2380-8	2.2	219
365	Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Blood*, **2011**, 118, 3080-7	2.2	218
364	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. *Blood*, **2015**, 126, 964-71	2.2	217
363	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. *Nature Communications*, **2015**, 6, 6604	17.4	215
362	Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. *Leukemia*, **2010**, 24, 285-97	10.7	209
361	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. *Nature Genetics*, **2013**, 45, 1494-8	36.3	205
360	Outcomes after induction failure in childhood acute lymphoblastic leukemia. *New England Journal of Medicine*, **2012**, 366, 1371-81	59.2	202
359	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. *Nature Genetics*, **2011**, 43, 237-41	36.3	201
358	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. *Nature Genetics*, **2019**, 51, 296-307	36.3	189
357	Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. *Leukemia*, **2010**, 24, 355-70	10.7	186
356	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. *Blood*, **2012**, 119, 3512-22	2.2	181
355	Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. *Journal of Clinical Oncology*, **2008**, 26, 3971-8	2.2	180
354	Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. *JAMA - Journal of the American Medical Association*, **2015**, 313, 815-23	27.4	179
353	Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. *JAMA - Journal of the American Medical Association*, **2009**, 301, 393-403	27.4	174
352	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. *Blood*, **2017**, 129, 3352-3361	2.2	168
351	Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. *Journal of the National Cancer Institute*, **2013**, 105, 733-42	9.7	167

350	Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. *Journal of Clinical Oncology*, **2012**, 30, 2545-51	2.2	165
349	Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. *Blood*, **2010**, 115, 1394-405	2.2	163
348	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. *Blood*, **2008**, 112, 4178-83	2.2	157
347	Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. *Journal of Clinical Oncology*, **2007**, 25, 501-6	2.2	146
346	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. *Nature Genetics*, **2016**, 48, 1481-1489	36.3	145
345	The genetic basis and cell of origin of mixed phenotype acute leukaemia. *Nature*, **2018**, 562, 373-379	50.4	140
344	Genome-wide study of methotrexate clearance replicates SLCO1B1. *Blood*, **2013**, 121, 898-904	2.2	137
343	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. *Blood*, **2013**, 121, 485-8	2.2	136
342	An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. *Leukemia*, **2014**, 28, 1015-21	10.7	134
341	Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. *Blood*, **2006**, 107, 4061-7	2.2	133
340	ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. *Journal of Clinical Oncology*, **2012**, 30, 751-7	2.2	131
339	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. *Nature Communications*, **2016**, 7, 13331	17.4	128
338	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. *Lancet Oncology, The*, **2015**, 16, 1659-66	21.7	123
337	Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. *Pediatric Blood and Cancer*, **2013**, 60, 957-63	3	121
336	Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. *Lancet Oncology, The*, **2012**, 13, 906-15	21.7	121
335	Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). *Blood*, **2011**, 118, 874-83	2.2	121
334	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. *Journal of Clinical Oncology*, **2018**, 36, 2306-2314	2.2	119
333	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 11306-11311	11.5	117

332	The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Leukemia*, **2009**, 23, 1417-25	10.7	113
331	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. *Blood*, **2018**, 131, 995-999	2.2	112
330	Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. *Journal of Clinical Oncology*, **2016**, 34, 854-62	2.2	112
329	Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group. *Journal of Clinical Oncology*, **2006**, 24, 152-9	2.2	112
328	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. *Blood*, **2018**, 131, 1350-1359	2.2	108
327	Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Blood*, **2011**, 118, 243-51	2.2	108
326	Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. *Journal of Clinical Oncology*, **2002**, 20, 426-33	2.2	108
325	Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. *Journal of Clinical Oncology*, **2009**, 27, 5189-94	2.2	102
324	Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. *European Journal of Cancer*, **2011**, 47, 724-31	7.5	101
323	Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. *Journal of Clinical Oncology*, **2013**, 31, 2469-76	2.2	100
322	A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Blood*, **2008**, 111, 4496-9	2.2	100
321	Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. *Journal of Clinical Oncology*, **2013**, 31, 3397-402	2.2	99
320	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. *Cancer Cell*, **2018**, 33, 937-948.e8	24.3	98
319	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. *Journal of Clinical Oncology*, **2018**, 36, 2926-2934	2.2	95
318	Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group. *Cancer*, **2015**, 121, 467-75	6.4	94
317	Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. *Blood*, **2012**, 120, 4197-204	2.2	89
316	Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. *Journal of Clinical Oncology*, **2005**, 23, 4031-8	2.2	89
315	Functional outcome after thoracoabdominal aortic aneurysm repair. *Journal of Vascular Surgery*, **2002**, 35, 640-7	3.5	89

314	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. *Blood*, **2015**, 126, 1770-6	2.2	86
313	Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. *Annals of Surgery*, **2003**, 238, 563-7; discussion 567-8	7.8	85
312	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. *Journal of Clinical Oncology*, **2018**, 36, 591-599	2.2	85
311	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. *Blood*, **2015**, 125, 680-6	2.2	84
310	Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. *Blood*, **2012**, 119, 1872-81	2.2	84
309	Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. *Journal of Clinical Oncology*, **2006**, 24, 3142-9	2.2	84
308	T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children's Oncology Group (COG) Study AALL0434. *Blood*, **2014**, 124, 1-1	2.2	80
307	Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. *Pediatric Blood and Cancer*, **2015**, 62, 1171-5	3	79
306	A prospective study of anxiety, depression, and behavioral changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Cancer*, **2014**, 120, 1417-25	6.4	79
305	Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. *Journal of Clinical Oncology*, **2016**, 34, 919-26	2.2	78
304	Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. *British Journal of Haematology*, **2009**, 144, 930-2	4.5	76
303	Axial transformation of the profunda femoris vein. *Journal of Vascular Surgery*, **1998**, 27, 651-9	3.5	75
302	Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia. *Genome Research*, **2012**, 22, 1833-44	9.7	72
301	Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. *Journal of Clinical Oncology*, **2011**, 29, 214-22	2.2	72
300	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. *Blood*, **2014**, 124, 1266-76	2.2	70
299	Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. *Journal of Clinical Oncology*, **2014**, 32, 3874-82	2.2	66
298	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. *Pediatric Blood and Cancer*, **2015**, 62, 1176-83	3	65
297	Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Journal of Clinical Oncology*, **2012**, 30, 2753-9	2.2	65

296	Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. *Blood*, **2010**, 116, 1045-50	2.2	63
295	Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. *Journal of Clinical Oncology*, **2008**, 26, 2186-91	2.2	62
294	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. *Blood*, **2018**, 132, 815-824	2.2	58
293	Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. *Blood*, **2011**, 117, 3010-5	2.2	58
292	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, **2016**, 34, 2133-40	2.2	57
291	Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. *Pediatric Blood and Cancer*, **2016**, 63, 54-61	3	57
290	Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. *The American Journal of Pediatric Hematology/oncology*, **2001**, 23, 340-8		55
289	Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. *Blood*, **2013**, 122, 507-14	2.2	54
288	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. *Blood*, **2015**, 126, 69-75	2.2	54
287	Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 325, 833-842	27.4	54
286	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. *Journal of Clinical Oncology*, **2020**, 38, 602-612	2.2	52
285	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. *Nature Communications*, **2015**, 6, 7553	17.4	51
284	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, **2020**, 38, 3282-3293	2.2	51
283	Perforin polymorphism A91V and susceptibility to B-precursor childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Leukemia*, **2006**, 20, 1539-41	10.7	50
282	Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. *Blood*, **2013**, 121, 2689-703	2.2	49
281	Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. *Journal of Clinical Oncology*, **2020**, 38, 1897-1905	2.2	49
280	Psychopathologic risk factors for intentional and nonintentional injury. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 42, 711-5	9.4	48
279	Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group. *Cancer*, **2016**, 122, 1116-25	6.4	47

278	Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. *Leukemia*, **2008**, 22, 281-6	10.7	47
277	Production of interleukin-10 in human fracture soft-tissue hematomas. *Shock*, **1996**, 6, 3-6	3.4	47
276	Glucose given after hypoxic ischemia does not affect brain injury in piglets. *Stroke*, **1994**, 25, 1443-7; discussion 1448	6.7	47
275	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. *Blood*, **2016**, 127, 558-64	2.2	47
274	Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study. *Cancer*, **2016**, 122, 1608-17	6.4	46
273	COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.. *Journal of Clinical Oncology*, **2018**, 36, 10500-10500	2.2	46
272	Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study. *The Lancet Child and Adolescent Health*, **2021**, 5, 332-340	14.5	46
271	Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. *Pediatric Blood and Cancer*, **2011**, 57, 569-77	3	45
270	Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. *Blood*, **2007**, 110, 1105-11	2.2	45
269	Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331. *International Journal of Cancer*, **2016**, 138, 332-9	7.5	44
268	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. *Journal of Clinical Oncology*, **2017**, 35, 2527-2534	2.2	43
267	Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Blood*, **2007**, 110, 1429-38	2.2	41
266	Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). *Pediatric Blood and Cancer*, **2015**, 62, 419-26	3	39
265	Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. *Clinical Cancer Research*, **2003**, 9, 837-44	12.9	39
264	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. *Leukemia*, **2018**, 32, 2126-2137	10.7	38
263	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2018**, 65, e26873	3	37
262	Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. *Leukemia*, **2011**, 25, 1555-63	10.7	36
261	Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Blood*, **2008**, 111, 2984-90	2.2	36

260	Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. *Clinical Pharmacology and Therapeutics*, **2017**, 102, 131-140	6.1	35
259	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331. *Blood*, **2019**, 134, LBA-1-LBA-1	2.2	34
258	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. *Journal of Clinical Oncology*, **2019**, 37, 780-789	2.2	33
257	Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5,659 children. *British Journal of Haematology*, **2010**, 149, 722-33	4.5	32
256	Saphenectomy in the presence of chronic venous obstruction. *Surgery*, **1998**, 123, 637-644	3.6	31
255	Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. *British Journal of Haematology*, **2019**, 186, 274-285	4.5	30
254	MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children's Oncology Group Study. *Leukemia*, **2016**, 30, 1909-12	10.7	29
253	Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). *Blood*, **2013**, 122, 3903-3903	2.2	29
252	Novel susceptibility variants at the locus for childhood acute lymphoblastic leukemia in Hispanics. *Blood*, **2019**, 133, 724-729	2.2	29
251	Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2015**, 62, 414-8	3	28
250	Survivors of standard risk acute lymphoblastic leukemia do not have increased risk for overweight and obesity compared to non-cancer peers: a report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2015**, 62, 1035-41	3	28
249	A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621. *Blood*, **2019**, 134, 741-741	2.2	28
248	Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. *Lancet Oncology, The*, **2021**, 22, 1416-1426	21.7	27
247	Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407. *Pediatric Blood and Cancer*, **2012**, 59, 834-9	3	26
246	Venous valve station changes in "primary" and postthrombotic reflux: an analysis of 149 cases. *Annals of Vascular Surgery*, **2000**, 14, 193-9	1.7	26
245	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. *Journal of Experimental Medicine*, **2018**, 215, 3094-3114	16.6	26
244	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). *Leukemia*, **2018**, 32, 1370-1379	10.7	25
243	Family life events in the first year of acute lymphoblastic leukemia therapy: a children's oncology group report. *Pediatric Blood and Cancer*, **2014**, 61, 2277-84	3	25

242	The use of central laboratories and remote electronic data capture to risk-adjust therapy for pediatric acute lymphoblastic leukemia and neuroblastoma. *Seminars in Oncology*, **2010**, 37, 53-9	5.5	25
241	Severe pegaspargase hypersensitivity reaction rates (grade 3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. *Leukemia and Lymphoma*, **2018**, 59, 1624-1633	1.9	24
240	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. *Blood*, **2019**, 134, 1227-1237	2.2	23
239	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. *Journal of Clinical Oncology*, **2020**, 38, 3062-3070	2.2	22
238	Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. *British Journal of Haematology*, **2009**, 145, 376-88	4.5	22
237	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. *Cancer Genetics*, **2019**, 238, 62-68	2.3	21
236	Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031. *Leukemia*, **2014**, 28, 964-7	10.7	21
235	Germline genetic variation and treatment response on CCG-1891. *Pediatric Blood and Cancer*, **2012**, 58, 695-700	3	21
234	A comparison of two different bronchial cuff designs and four different bronchial cuff inflation methods. *Journal of Cardiothoracic and Vascular Anesthesia*, **1997**, 11, 599-603	2.1	21
233	Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. *Journal of Clinical Oncology*, **2017**, 35, 2700-2707	2.2	20
232	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. *Journal of the National Cancer Institute*, **2019**, 111, 1350-1357	9.7	19
231	Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. *Pediatric Blood and Cancer*, **2018**, 65, e26928	3	19
230	Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. *Leukemia*, **2011**, 25, 1365-8	10.7	19
229	Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Clinical Cancer Research*, **2007**, 13, 451-7	12.9	19
228	Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2. *Blood*, **2011**, 118, 573-573	2.2	19
227	Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. *Oncogene*, **2019**, 38, 2241-2262	7.2	19
226	Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. *Leukemia*, **2017**, 31, 1325-1332	10.7	18
225	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. *Leukemia and Lymphoma*, **2019**, 60, 1740-1748	1.9	18

224	Higher Reported Lung Dose Received During Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukemia Is Associated With Inferior Survival: A Report from the Children's Oncology Group. *International Journal of Radiation Oncology Biology Physics*, **2019**, 104, 513-521	4	18
223	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. *Cancer*, **2018**, 124, 1150-1159	6.4	18
222	Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296. *Pediatric Blood and Cancer*, **2006**, 46, 179-86	3	18
221	Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. *Cancer*, **2020**, 126, 593-601	6.4	18
220	Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements. *Leukemia*, **2014**, 28, 428-30	10.7	17
219	Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. *Cancer Chemotherapy and Pharmacology*, **2014**, 74, 831-8	3.5	17
218	Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200□10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group. *British Journal of Haematology*, **2015**, 168, 533-46	4.5	17
217	Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children□ Oncology Group (COG) Study AALL0031.. *Blood*, **2007**, 110, 4-4	2.2	17
216	CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). *Blood*, **2017**, 130, 98-98	2.2	17
215	Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Journal of Pediatric Hematology/Oncology*, **2007**, 29, 369-75	1.2	16
214	Ambulatory Venous Hypertension: Component Analysis in 373 Limbs. *Vascular Surgery*, **1999**, 33, 257-266		16
213	Increased Incidence of Osteonecrosis (ON) with a Dexamethasone (DEX) Induction for High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report from the Children□ Oncology Group (COG).. *Blood*, **2008**, 112, 898-898	2.2	16
212	Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children□ Oncology Group (COG) study.. *Journal of Clinical Oncology*, **2019**, 37, 10008-10008	2.2	15
211	Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. *Cancer*, **2018**, 124, 571-579	6.4	15
210	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of induction□ A Children's Oncology Group (COG) Study.. *Blood*, **2009**, 114, 9-9	2.2	14
209	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children□ Oncology Group (COG) Study AALL0331. *Blood*, **2014**, 124, 793-793	2.2	13
208	Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Journal of Pediatric Hematology/Oncology*, **2012**, 34, e1-7	1.2	12
207	Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project.. *Blood*, **2009**, 114, 704-704	2.2	12

206	Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies. *Pediatric Blood and Cancer*, **2016**, 63, 255-61	3	12
205	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. *Haematologica*, **2019**, 104, 986-992	6.6	12
204	Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232. *Cancer Medicine*, **2018**, 7, 3-12	4.8	11
203	Pediatric acute lymphoblastic leukemia with a t(8;14)(q11.2;q32): B-cell disease with a high proportion of Down syndrome: a Children's Oncology Group study. *Cancer Genetics*, **2012**, 205, 453-8	2.3	11
202	Expression of CD44, but not CD44v6, predicts relapse in children with B cell progenitor acute lymphoblastic leukemia lacking adverse or favorable genetics. *Leukemia and Lymphoma*, **2008**, 49, 710-8	1.9	11
201	A method for determining patient oral care skills: The University of Mississippi Oral Hygiene Index. *Journal of Periodontology*, **1998**, 69, 1176-80	4.6	11
200	Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434. *Blood*, **2015**, 126, 794-794	2.2	11
199	Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL).. *Journal of Clinical Oncology*, **2012**, 30, 9504-9504	2.2	11
198	Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433. *Haematologica*, **2021**, 106, 46-55	6.6	10
197	Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia. *Leukemia Research*, **2010**, 34, 1601-9	2.7	10
196	Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: A Children's Oncology Group (COG) study (AALL07P1).. *Journal of Clinical Oncology*, **2013**, 31, 10003-10003	2.2	10
195	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. *Journal of Clinical Oncology*, **2021**, 39, 1437-1447	2.2	10
194	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. *Journal of Clinical Oncology*, **2020**, 38, 2628-2638	2.2	9
193	Prognostic significance of cytogenetically detected chromosome 21 anomalies in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. *Cancer Genetics and Cytogenetics*, **2007**, 175, 117-24		9
192	Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a pediatric oncology group pilot feasibility study. *Journal of Pediatric Hematology/Oncology*, **2006**, 28, 210-5	1.2	9
191	Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children's Oncology Group Study 1991. *Blood*, **2008**, 112, 9-9	2.2	9
190	TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232. *Blood*, **2011**, 118, 1510-1510	2.2	9
189	Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children's Oncology Group (COG) AALL0331. *Blood*, **2013**, 122, 837-837	2.2	9

188	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. *Blood Advances*, **2021**, 5, 504-512	7.8	9
187	TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2014**, 61, 2086-8	3	8
186	Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group. *Journal of Pediatric Hematology/Oncology*, **2014**, 36, 353-61	1.2	8
185	Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231. *Blood*, **2020**, 136, 11-12	2.2	8
184	Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. *Blood Advances*, **2019**, 3, 1647-1656	7.8	8
183	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group. *Haematologica*, **2019**, 104, e517-e520	6.6	7
182	One- and two-stage designs for phase II window studies. *Statistics in Medicine*, **2007**, 26, 2604-14	2.3	7
181	Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Children Oncology Group AALL0622.. *Journal of Clinical Oncology*, **2015**, 33, 10006-10006	2.2	7
180	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. *Nature Cancer*, **2020**, 1, 1113-1127	15.4	7
179	Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. *Journal of the National Cancer Institute*, **2021**, 113, 408-417	9.7	7
178	The Global COVID-19 Observatory and Resource Center for Childhood Cancer: A response for the pediatric oncology community by SIOP and St. Jude Global. *Pediatric Blood and Cancer*, **2021**, 68, e28962	3	7
177	Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia. *JNCI Cancer Spectrum*, **2018**, 2, pky069	4.6	7
176	Dysregulated transcriptional networks in and -rearranged T-ALL. *Biomarker Research*, **2018**, 6, 27	8	7
175	Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia. *Clinical Investigation*, **2013**, 3,		6
174	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. *Blood*, **2018**, 132, 35-35	2.2	6
173	Treatment of High Risk T-Cell Acute Lymphoblastic Leukemia (T-ALL): Comparison of Recent Experience of the Children Cancer Group (CCG) and Pediatric Oncology Group (POG).. *Blood*, **2004**, 104, 681-681	2.2	6
172	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. *Blood*, **2009**, 114, 1580-1580	2.2	6
171	Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 232-232	2.2	6

170	Incidence of Allergic Reactions to Pegaspargase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B-Lymphoblastic Leukemia (HR B-ALL): Results of Children's Oncology Group (COG) Studies AALL0232/AALL1131. *Blood*, **2015**, 126, 1303-1303	2.2	6
169	The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. *Blood*, **2021**, 138, 1677-1690	2.2	6
168	A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. *Journal of Pediatric Hematology/Oncology*, **2016**, 38, 409-17	1.2	6
167	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. *Leukemia*, **2021**, 35, 1279-1290	10.7	6
166	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. *Journal of Clinical Investigation*, **2021**,	15.9	6
165	Six Candidate miRNAs Associated With Early Relapse in Pediatric B-Cell Acute Lymphoblastic Leukemia. *Anticancer Research*, **2020**, 40, 3147-3153	2.3	5
164	Treatment of relapsed precursor-B acute lymphoblastic leukemia with intensive chemotherapy: POG (Pediatric Oncology Group) study 9411 (SIMAL 9). *Journal of Pediatric Hematology/Oncology*, **2013**, 35, 509-13	1.2	5
163	Prognostic Significance of Minimal Residual Disease (MRD) in Children with High Risk Acute Lymphoblastic Leukemia(ALL) A Children Oncology Group Study.. *Blood*, **2005**, 106, 85-85	2.2	5
162	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 618-618	2.2	5
161	Effect of High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Pegaspargase (C-MTX/ASNase) on Osteonecrosis (ON) Incidence in Children and Young Adults with T-Acute Lymphoblastic Leukemia (T-ALL): Results of Children Oncology Group (COG) Study AALL0434. *Blood*, **2014**, 124, 3640-3640	2.2	5
160	Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131. *Blood*, **2015**, 126, 2502-2502	2.2	5
159	Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HR-ALL): A report from the Children Oncology Group study AALL0232.. *Journal of Clinical Oncology*, **2012**, 30, CRA9508-CRA9508	2.2	5
158	Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905. *Leukemia*, **2020**, 34, 1006-1016	10.7	5
157	Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children. *Journal of the National Cancer Institute*, **2021**, 113, 933-937	9.7	5
156	Replication timing alterations in leukemia affect clinically relevant chromosome domains. *Blood Advances*, **2019**, 3, 3201-3213	7.8	5
155	FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study. *Blood*, **2019**, 134, 1293-1293	2.2	4
154	Increased Infection-Related Mortality for Children with Down Syndrome (DS) in Contemporary Children Oncology Group (COG) Acute Lymphoblastic Leukemia (ALL) Clinical Trials.. *Blood*, **2006**, 108, 1865-1865	2.2	4
153	Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children Oncology Group (COG) Study.. *Blood*, **2006**, 108, 219-219	2.2	4

152	Report On Excessive Induction Toxicity in Infants with ALL Enrolled On COG Protocol AALL0631: A Children's Oncology Group Study.. *Blood*, **2009**, 114, 3091-3091	2.2	4
151	Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project.. *Blood*, **2009**, 114, 85-85	2.2	4
150	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. *Blood*, **2012**, 120, 137-137	2.2	4
149	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. *Blood*, **2013**, 122, 825-825	2.2	4
148	Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children's Oncology Group (COG) AALL0433. *Blood*, **2014**, 124, 684-684	2.2	4
147	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). *Blood*, **2015**, 126, 807-807	2.2	4
146	Assessment of end induction minimal residual disease (MRD) in childhood B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for day 14 marrow examination: A Children Oncology Group study.. *Journal of Clinical Oncology*, **2013**, 31, 10001-10001	2.2	4
145	IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 289-289	2.2	4
144	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 794-802	6.1	4
143	Favorable Trisomies and Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. *Journal of Clinical Oncology*, **2021**, 39, 1540-1552	2.2	4
142	Global Experiences of Pediatric Palliative Care Teams During the First 6 Months of the SARS-CoV-2 Pandemic. *Journal of Pain and Symptom Management*, **2021**, 62, e91-e99	4.8	4
141	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. *Pediatric Blood and Cancer*, **2019**, 66, e27681	3	3
140	Reply to A. Bleyer et al. *Journal of Clinical Oncology*, **2012**, 30, 4038-4039	2.2	3
139	Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.. *Journal of Clinical Oncology*, **2022**, JCO2101693	2.2	3
138	Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group. *Blood*, **2020**, 136, 45-46	2.2	3
137	Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.. *Blood*, **2004**, 104, 680-680	2.2	3
136	Specific MLL Partner Genes in Infant Acute Lymphoblastic Leukemia (ALL) Associated with Outcome Are Linked to Age and White Blood Cell Count (WBC) at Diagnosis: A Report On the Children's Oncology Group (COG) P9407 Trial.. *Blood*, **2009**, 114, 907-907	2.2	3
135	Genome-Wide Analysis of Genetic Alterations In Hypodiploid Acute Lymphoblastic Leukemia Identifies a High Frequency of Mutations Targeting the IKAROS Gene Family and Ras Signaling. *Blood*, **2010**, 116, 411-411	2.2	3

134	Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. *Blood*, **2011**, 118, 1440-1440	2.2	3
133	Effects of Dexamethasone (DEX) Vs Prednisone (PDN) and High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Asparaginase (C-MTX/ASNase) On Osteonecrosis (ON) Incidence in Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From the Children's Oncology Group (COG) Study AALL0232. *Blood*, **2012**, 120, 665-665	2.2	3
132	Comparison Of Mutational Profiles Of Diagnosis and Relapsed Pediatric B-Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. *Blood*, **2013**, 122, 824-824	2.2	3
131	The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 691-691	2.2	3
130	Anti-Pegaspargase, Anti-Calaspargase Pegol , and Anti-Polyethelene Glycol Antibody Incidence in High Risk Acute Lymphoblastic Leukemia Patients Receiving Pegaspargase or Calaspargase Pegol and Associated Anaphylactic or Hypersensitivity Reaction Rates: Results from Children's Oncology Group (COG) Study AALL07P4. *Blood*, **2016**, 128, 3965-3965	2.2	3
129	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. *Blood*, **2016**, 128, 451-451	2.2	3
128	Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. *Blood*, **2016**, 128, 454-454	2.2	3
127	The significance of minimal residual disease (MRD) in relapsed childhood B-lymphoblastic leukemia (B-ALL): A report from Children Oncology Group (COG) protocol AALL0433.. *Journal of Clinical Oncology*, **2014**, 32, 10014-10014	2.2	3
126	Plasma asparaginase activity and asparagine depletion in patients with acute lymphoblastic leukemia (ALL) treated with pegaspargase (SS-PEG E. coli L-asparaginase): Results from Children Oncology Group (COG) study AALL07P4.. *Journal of Clinical Oncology*, **2016**, 34, 10508-10508	2.2	3
125	Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731. *Blood*, **2021**, 138, 2304-2304	2.2	3
124	Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group. *Leukemia*, **2019**, 33, 2144-2154	10.7	3
123	Physician Perceptions of Palliative Care for Children With Cancer in Latin America.. *JAMA Network Open*, **2022**, 5, e221245	10.4	3
122	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.. *Journal of Clinical Oncology*, **2022** , JCO2102678	2.2	3
121	Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952. *Leukemia Research Reports*, **2015**, 4, 47-50	0.6	2
120	Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia. *British Journal of Haematology*, **2017**, 179, 843-846	4.5	2
119	Chemotherapy for initial induction failures in childhood acute lymphoblastic leukemia: a Children's Oncology Group Study (POG 8764). *Journal of Pediatric Hematology/Oncology*, **2013**, 35, 32-5	1.2	2
118	Generalized logistic models for low-dose response data. *Statistics in Medicine*, **1993**, 12, 881-92	2.3	2
117	Impact of the COVID-19 pandemic on pediatric oncology providers globally: A mixed-methods study.. *Cancer*, **2022**,	6.4	2

116	Minimal Residual Disease(MRD) in Childhood Acute Lymphoblastic Leukemia(ALL) in Relapse. A Children Oncology Group (COG) Study.. *Blood*, **2004**, 104, 324-324	2.2	2
115	A Report of the Event-Free Survival (EFS) and Neurotoxicity for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) on Pediatric Oncology Group (POG) Protocol 9405.. *Blood*, **2005**, 106, 882-882	2.2	2
114	Nelarabine Can Be Safely Incorporated into an Intensive, Multiagent Chemotherapy Regimen for the Treatment of T-Cell Acute Lymphocytic Leukemia (ALL) in Children: A Report of the Children Oncology Group (COG) AALL00P2 Protocol for T-Cell Leukemia.. *Blood*, **2006**, 108, 1864-1864	2.2	2
113	Outcomes of Children with First Marrow Relapse: Results from Children Oncology Group (COG) Study AALL01P2.. *Blood*, **2006**, 108, 1871-1871	2.2	2
112	Genome-Wide Profiling of High-Risk Pediatric Acute Lymphoblastic Leukemia (ALL): The ALL Pilot Project for the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) Initiative.. *Blood*, **2007**, 110, 229-229	2.2	2
111	Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG).. *Blood*	2.2	2
110	Lack of Somatic Sequence Mutations In Protein Tyrosine Kinase Genes Other Than the JAK Kinase Family In High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. *Blood*, **2010**, 116, 2752-2752	2.2	2
109	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. *Blood*, **2016**, 128, 1086-1086	2.2	2
108	Safety and biological activity of the FLT3 inhibitor lestaurtinib in infant MLL-rearranged (MLL-r) ALL: Children's Oncology Group protocol AALL0631.. *Journal of Clinical Oncology*, **2012**, 30, 9548-9548	2.2	2
107	Interdisciplinary care of pediatric oncology patients in Central America and the Caribbean. *Cancer*, **2021**, 127, 2579-2586	6.4	2
106	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. *Blood* , **2021**, 137, 1550-1552	2.2	2
105	The T681I mutation is highly resistant to imatinib and dasatinib and detectable in clinical samples prior to treatment. *Haematologica*, **2021**, 106, 2242-2245	6.6	2
104	Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report.. *Cancer*, **2022**,	6.4	2
103	Reply to I.J. Cohen. *Journal of Clinical Oncology*, **2017**, 35, 3989-3991	2.2	1
102	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children Oncology Group (COG). *Leukemia*, **2017**,	10.7	1
101	Does intravenous 6-mercaptopurine decrease salvage after relapse in childhood acute lymphoblastic leukemia?. *Pediatric Blood and Cancer*, **2006**, 46, 660-1	3	1
100	Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method. *British Journal of Haematology*, **2006**, 135, 358-61	4.5	1
99	Low-dose extrapolation using the power family of response functions. *Computational Statistics and Data Analysis*, **2001**, 36, 311-317	1.6	1

98	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). *Blood*, **2020**, 136, 44-45	2.2	1
97	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). *Blood*, **2018**, 132, 1000-1000	2.2	1
96	Germline RUNX1 Variation and Predisposition to T-Cell Acute Lymphoblastic Leukemia in Children. *Blood*, **2019**, 134, 653-653	2.2	1
95	Thrombotic and Hemorrhagic Events for Patients on Pediatric Oncology Group (POG) Protocols 9201, 9605, 9406.. *Blood*, **2005**, 106, 880-880	2.2	1
94	Prevalence and Clinical Correlates of JAK2 Mutations in Pediatric Down Syndrome Acute Lymphoblastic Leukemia.. *Blood*, **2008**, 112, 1506-1506	2.2	1
93	Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children Oncology Group (COG) Study AALL0031.. *Blood*, **2008**, 112, 911-911	2.2	1
92	Gene Expression Profiling in Down Syndrome Acute Lymphoblastic Leukemia Identifies Distinct Profiles Associated with CRLF2 Expression Status.. *Blood*, **2009**, 114, 2389-2389	2.2	1
91	Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.. *Blood*, **2009**, 114, 320-320	2.2	1
90	T-Cell Receptor Gene Deletions Are Associated with High Risk Features and Worse Outcome In Childhood Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). *Blood*, **2010**, 116, 275-275	2.2	1
89	Infant Acute Lymphoblastic Leukemias Are Pan-Sensitive to Obatoclax Across molecular/Cytogenetic Subtypes, Especially MLL-ENL, and gene Expression Profiles Determine Obatoclax IC50: A Report on the Children's Oncology Group (COG) P9407 Trial. *Blood*, **2010**, 116, 2757-2757	2.2	1
88	Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991. *Blood*, **2010**, 116, 497-497	2.2	1
87	A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232. *Blood*, **2011**, 118, 743-743	2.2	1
86	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. *Blood*, **2012**, 120, 2466-2466	2.2	1
85	Identification of CRLF2 Genomic Lesions in Patients with Pediatric B-Precursor Acute Lymphoblastic Leukemia (BCP ALL) by Flow Cytometry or Quantitative RT-PCR: A Children's Oncology Group (COG) Stud.. *Blood*, **2012**, 120, 2529-2529	2.2	1
84	Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. *Blood*, **2013**, 122, 3736-3736	2.2	1
83	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 60-60	2.2	1
82	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. *Blood*, **2014**, 124, 367-367	2.2	1
81	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 693-693	2.2	1

80	Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. *Blood*, **2015**, 126, 694-694	2.2	1
79	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. *Blood*, **2016**, 128, 1085-1085	2.2	1
78	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 604-604	2.2	1
77	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). *Blood*, **2016**, 128, 758-758	2.2	1
76	Evaluation of local control strategies in patients with localized Ewing sarcoma of bone: A report from the Children Oncology Group.. *Journal of Clinical Oncology*, **2012**, 30, 9537-9537	2.2	1
75	Effect of dexamethasone (DEX) dose modification on osteonecrosis (ON) risk associated with intensified therapies for standard risk acute lymphoblastic leukemia (SR-ALL): A report from the Children Oncology Group (COG) study AALL0331.. *Journal of Clinical Oncology*, **2013**, 31, 10002-10002	2.2	1
74	The impact of initial cerebrospinal fluid (CSF) findings on outcome among patients with NCI standard (SR) and high-risk (HR) B-lymphoblastic leukemia (ALL): A report from the Children Oncology Group (COG) Studies AALL0331 and AALL0232.. *Journal of Clinical Oncology*, **2014**, 32, 10016-10016	2.2	1
73	Prospective assessment of chemotherapy-induced peripheral neuropathy (CIPN) in children with standard-risk acute lymphoblastic leukemia (SR ALL): Results of Children Oncology Group (COG) AALL0932.. *Journal of Clinical Oncology*, **2014**, 32, 7056-7056	2.2	1
72	Communication Priorities and Experiences of Caregivers of Children With Cancer in Guatemala. *JCO Global Oncology*, **2021**, 7, 1529-1536	3.7	1
71	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331. *Blood*, **2021**, 138, 363-363	2.2	1
70	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. *Blood*, **2021**, 138, 3398-3398	2.2	1
69	Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study. *Blood*, **2021**, 138, 211-211	2.2	1
68	Outcomes after HLA-Matched Sibling Transplants or Chemotherapy in Children with Acute Lymphoblastic Leukemia in a Second Remission after an Isolated Central Nervous System Relapse.. *Blood*, **2006**, 108, 49-49	2.2	1
67	Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group. *Blood*, **2017**, 130, 883-883	2.2	1
66	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. *Blood*, **2018**, 132, 565-565	2.2	1
65	Reliability and validity of a Spanish-language measure assessing clinical capacity to sustain Paediatric Early Warning Systems (PEWS) in resource-limited hospitals. *BMJ Open*, **2021**, 11, e053116	3	1
64	Variable Retention of Differentiation-specific DNA Replication Timing in Human Pediatric Leukemia		1
63	Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG).. *Blood*, **2009**, 114, 2598-2598	2.2	1

62	Nelarabine May Be Safely Incorporated Into a Phase III Study for Newly Diagnosed T-Lineage Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. *Blood*, **2010**, 116, 865-865	2.2	1
61	iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. *Blood*, **2011**, 118, 739-739	2.2	1
60	Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children Oncology Group AALL1131.. *Journal of Clinical Oncology*, **2021**, 39, 10004-10004	2.2	1
59	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. *Blood Advances*, **2021**, 5, 2890-2900	7.8	1
58	Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2. *Pediatric Blood and Cancer*, **2021**, 68, e29256	3	1
57	EPID-05. A novel, clinically-relevant classification of pediatric CNS tumors for cancer registries using a clustering analysis. *Neuro-Oncology*, **2022**, 24, i47-i47	1	1
56	Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group. *Blood*, **2016**, 128, 455-455	2.2	0
55	Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia. *Blood*, **2008**, 112, 14-14	2.2	0
54	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations. *Blood*, **2012**, 120, 877-877	2.2	0
53	Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. *Pediatric Blood and Cancer* , **2021**, 68, e28929	3	0
52	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. *Blood*, **2020**, 136, 39-40	2.2	
51	Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report. *Blood*, **2020**, 136, 38-39	2.2	
50	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. *Blood*, **2021**, 138, 2382-2382	2.2	
49	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2021**, 138, 3487-3487	2.2	
48	The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia. *Blood*, **2021**, 138, 3476-3476	2.2	
47	Non-Classical Monocyte Abundance Is an Independent Adverse Risk Factor for Relapse in Pediatric B-ALL. *Blood*, **2021**, 138, 1316-1316	2.2	
46	Pharmacogenetics of Minimal Residual Disease Response in Children with Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2004**, 104, 451-451	2.2	
45	A Report of the Event Free Survival (EFS) for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) Treated on Pediatric Oncology Group (POG) Protocol 9605.. *Blood*, **2005**, 106, 875-875	2.2	

44	Perforin Polymorphism A91V and Susceptibility to Childhood Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2005**, 106, 1453-1453	2.2
43	Prospective Analysis of TEL and MLL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children Oncology Group Study.. *Blood*, **2006**, 108, 218-218	2.2
42	Testicular Relapse in Lesser, Standard, and High Risk Patients Treated with Frontline Therapy for Childhood ALL. Pediatric Oncology Group Protocols 9201, 9405, 9605, and 9406.. *Blood*, **2006**, 108, 1863-1863	2.2
41	Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric High-Risk B Precursor Acute Lymphoblastic Leukemia (ALL): A Children Oncology Group Study.. *Blood*, **2007**, 110, 1422-1422	2.2
40	Possible Advantage of Twice-Daily 6-Mercaptopurine Dosing in Children with Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2007**, 110, 851-851	2.2
39	Outcomes for B-Precursor Patients in Legacy Children Cancer Group (CCG) and Pediatric Oncology Group (POG) Studies in Childhood Acute Lymphoblastic Leukemia (ALL): A Children Oncology Group (COG) Report.. *Blood*, **2007**, 110, 847-847	2.2
38	Expression Profiling Identifies Novel Genetic Subgroups with Distinct Clinical Features and Outcome in High-Risk Pediatric Precursor B Acute Lymphoblastic Leukemia (B-ALL). A Children Oncology Group Study.. *Blood*, **2007**, 110, 1430-1430	2.2
37	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. *Blood*, **2018**, 132, 659-659	2.2
36	Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232. *Blood*, **2019**, 134, 286-286	2.2
35	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. *Blood*, **2014**, 124, 63-63	2.2
34	Resource Utilization and Cost Analysis By Treatment Arm on the Children Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children Oncology Group. *Blood*, **2014**, 124, 210-210	2.2
33	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 695-695	2.2
32	Mutational Landscape, Clonal Evolution Patterns and Role of RAS Mutations in Relapsed Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 4068-4068	2.2
31	Integrated Genomic Analysis of Down Syndrome Acute Lymphoblastic Leukemia Reveals Recurrent Cancer Gene Alterations and Evidence of Frequent Subclonal Driver Events. *Blood*, **2016**, 128, 4083-4083	2.2
30	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 2906-2906	2.2
29	Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 759-759	2.2
28	Longitudinal analysis of quality of life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children Oncology Group (COG) AALL0932.. *Journal of Clinical Oncology*, **2017**, 35, 10522-10522	2.2
27	Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children Oncology Group Study 1991. *Blood*, **2008**, 112, 701-701	2.2

26	Acute Lymphoblastic Leukemia (ALL) with t(8;14)(q11.2;q32): B-Lineage Disease with High Proportion of Down Syndrome. A Children Oncology Group (COG) Study.. *Blood*, **2008**, 112, 1477-1477	2.2
25	Evolution of Gene Expression Signatures in Relapsed Childhood Acute Lymphoblastic Leukemia Differs Based on Timing of Relapse.. *Blood*, **2008**, 112, 3345-3345	2.2
24	Pan-Anti-Apoptotic BCL-2 Family Inhibitor, Obatoclax, Activates Autophagic Cell Death Pathway and Has Potent Cytotoxicity in Infant and Pediatric MLL-Rearranged Leukemias. *Blood*, **2008**, 112, 2647-2647	2.2
23	Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Children Oncology Group (COG) Study.. *Blood*, **2008**, 112, 2256-2256	2.2
22	Quantitative RT-PCR for Expression of a Small Subset of Genes Identifies Novel Prognostic Subgroups in High-Risk Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia (HR-ALL): Clinical Applicability of Gene Expression Microarray Data from Children Oncology Group Trials.. *Blood*, **2008**, 112, 1514-1514	2.2
21	Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants.. *Blood*, **2008**, 112, 2255-2255	2.2
20	Survival after Relapse in Higher Risk Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Is Independent of Prior Treatment Intensity: A Report from the Children Oncology Group (COG).. *Blood*, **2008**, 112, 917-917	2.2
19	Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031.. *Blood*, **2009**, 114, 2606-2606	2.2
18	Strategies for New Agent Development and Clinical Trial Considerations. *Pediatric Oncology*, **2011**, 215-241	2.2
17	Early Response Characteristics and Blast Cytogenetic FEatures In 5,377 Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): A Children's Oncology Group (COG) Study. *Blood*, **2010**, 116, 414-414	2.2
16	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. *Blood*, **2010**, 116, 8-8	2.2
15	Administration of Erwinia Asparaginase (Erwinase) Following Allergy to PEG-Asparaginase In Children and Young Adults with Acute Lymphoblastic Leukemia Treated on AALL07P2 Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report From the Children's Oncology Group (COG).. *Blood*, **2010**, 116, 2134-2134	2.2
14	Longer Time to the Start of Continuation Therapy Is Associated with Improved Survival In High Risk Pediatric Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG). *Blood*, **2010**, 116, 3223-3223	2.2
13	Gene Expression Profiling Reveals Genes Predictive of Outcome In Infant Acute Lymphoblastic Leukemia (ALL) and Distinctive Age-Related Gene Expression Profiles (90 Days): A Children's Oncology Group Study. *Blood*, **2010**, 116, 412-412	2.2
12	Novel Chromosomal Rearrangements and Sequence Mutations in High-Risk Ph-Like Acute Lymphoblastic Leukemia. *Blood*, **2011**, 118, 67-67	2.2
11	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. *Blood*, **2011**, 118, 68-68	2.2
10	Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HR-ALL): A report from the Children Oncology Group study AALL0232.. *Journal of Clinical Oncology*, **2012**, 30, CRA9508-CRA9508	2.2
9	Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG e. coli L-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children's Oncology Group (COG) study AALL07P4.. *Journal of Clinical Oncology*, **2012**, 30, 9543-9543	2.2

8	Trends in body mass index (BMI) during and after treatment for standard risk (SR) acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group (COG).. *Journal of Clinical Oncology*, **2012**, 30, 9546-9546	2.2
7	Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort. *Blood*, **2012**, 120, 1440-1440	2.2
6	Expression Profiling for MEIS1 and HOXA9/10 Identifies an Increased Incidence of MLL Rearrangements in T-ALL: A Children's Oncology Group Study.. *Blood*, **2012**, 120, 2505-2505	2.2
5	Risk Factors For Acute Pancreatitis In Patients With Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 3868-3868	2.2
4	Leukemic Blasts With The PNH Phenotype: Correlation With Cytogenetics In ALL. *Blood*, **2013**, 122, 2628-2628	2.2
3	Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.. *Journal of Clinical Oncology*, **2021**, 39, 10002-10002	2.2
2	Prognostic Impact of CNS-2 status in T-ALL: A report from the Children's Oncology Group.. *Journal of Clinical Oncology*, **2021**, 39, 10003-10003	2.2
1	Reply to A. K. Agrawal et al. *Journal of Clinical Oncology*, **2021**, 39, 695-696	2.2